eUpdate Electronic Newsletter


Type 1 Diabetes Drug Effective In Stopping Beta Cell Destruction

Jeffrey Bluestone, PhDAn experimental drug that has been studied for nearly 20 years continues to show effectiveness in about half of the patients who participated in a recent phase 2 clinical trial.  The drug, Teplizumab -- also known as anti CD3, is designed to block the advance of type 1 diabetes in its earliest stages.

Recently published in the journal Diabetes, this promising research continues to be spearheaded by former Diabetes Center Director and current Executive Vice Chancellor and Provost, Jeffrey Bluestone, PhD<UCSF News Office>

Teplizumab is also being used in a type 1 diabetes prevention trial through TrialNet.  Family members of type 1s who screen positively for predictive autoantibodies may be eligible.  Screen online through  For more information: 415.502.0857;

New Immune Cell Discovery to Impact Autoimmune Diseases

Mark Anderson, MD., PhD.Mark Anderson, MD, PhD, and his colleagues have discovered a distinctive type of immune cell called an eTAC, which puts a damper on immune responses and could eventually lead to more effective treatments for autoimmune diseases including type 1 diabetes.

Recently published in the journal Immunity, Anderson’s research showed that eTACs counteract the overactive immune reponse in autoimmune diseases and may be manipulated to stop the destruction of the pancreas in a mouse model of type 1 diabetes.  <UCSF News Office>


Bluestone Elected to Institute of Medicine

Institute of MedicineExecutive Vice Chancellor and Provost Jeffrey Bluestone, PhD, was elected to the Institute of Medicine (IOM), one of the highest honors in the fields of health and medicine.  The IOM recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. Dr. Bluestone deserves this honor for his groundbreaking work in modulating immune responses in type 1 diabetes.

Established in 1970 by the National Academy of Sciences, IOM has become recognized as a national resource for independent, scientifically informed analysis and recommendations on health issues. With their election, members make a commitment to volunteer their service on IOM committees, boards, and other activities.  <UCSF News Office>

Free Diabetes Education Now Available Online Through Coursera

CourseraCoursera, one of the leading providers of MOOCs (or massive open online courses) is now offering a free course on diabetes taught by faculty members from throughout UCSF’s professional schools: Medicine, Nursing, Pharmacy and Dentistry.

Topics include epidemiology, diabetes diagnosis, nutritional strategies for self-management, the role of insulin in managing diabetes, effects of diabetes on oral/dental health, and current research in the field. The course started this week and runs through November 2013. You may sign up and review the curriculum here: diabetes education program.

Diabetes Public Health Specialist Recognized

Dean Schillinger, MD.This month, Dean Schillinger, MD, was awarded the 2013 Public Health Communications Research Award by the American Public Health Association (APHA). The APHA Everett Rogers Award is given to an individual who has made an outstanding contribution to advancing the study and/or practice of public health communication. <MORE>

Diabetes Public Health Specialist Recognized

Michael McManusRNA specialist, Michael McManus, PhD, received an NIH grant to explore and enhance our understanding of a recently discovered cell-to-cell messaging process called extracellular (outside the cell) RNA communication -- exRNA.

Dr. McManus will explore basic exRNA biology and develop tools and technologies that apply new knowledge about exRNA to the research, diagnosis and treatment of diseases.  <NIH Media Release>

New Research Institute Supports Physician-Scientist

was named a 2013Feroz Papa Harrington Scholar-Innovator by the Harrington Discovery Institute’s Scientific Advisory Board from a field of more than 130 applicants from 53 institutions.

Dr. Papa’s research focuses on protein misfolding in the endoplasmic reticulum (ER) to quantify and predict levels of ER stress that promote the death of pancreatic islet beta cells and determine the role of the unfolded protein response (UPR) in the cell death process.


Diabetes Prevention Focus of Clinical Trials, San Francisco Chronicle, October 30, 2013

California Supreme Court Ruling for Schoolchildren with Diabetes.

US Supreme CourtAfter years of legal and legislative challenges, the American Diabetes Association and DREDF won their battle to support California students with diabetes.  The California Supreme Court ruled that children may receive insulin from trained volunteers without having to wait for a school nurse.   <ADA Story>  <DREDF Story>  <San Francisco Chronicle>  <San Jose Mercury News>


The Diabetes Center at UCSF is among the premier institutions for clinical trials of emerging therapies in diabetes. Numerous clinical trials in type 1 and 2 diabetes are now underway.  Interested in participating? A sample of our trials is listed below.

TrialNet Natural History Study [Antibody Screening]. Seeking relatives of people with type 1 diabetes, 1 to 45 years of age

Type 1 Diabetes: An Oral Insulin Preventative Study. Seeking relatives of people with type 1 diabetes, 3 to 45 years of age

Type 1 Diabetes: Anti-CD3 mAB (Teplizumab) Preventative Study. Seeking relatives of people with type 1 diabetes, 8 to 45 years of age

Type 1 Diabetes: CTLA-4 lg (Abatacept) Preventative Study. Seeking relatives of people with type 1 diabetes, 6 to 45 years of age

Type 1 Diabetes: Evaluation of Residual Beta Cell Function and Immunologic Features in Patients with Longstanding Type 1 Diabetes. Seeking volunteers 8 years or older who have had type 1 diabetes for five or more years and have a hemoglobin A1c < 9.5%

Type 1 Diabetes: A Randomized Trial of Meformin as Adjunct Therapy for Overweight Adolescents Volunteers must be overweight, 12 to 19 years old, and have had diabetes for 1 or more years

Type 1 Diabetes: Safety and Efficacy of Imatinib for Preserving Beta-cell Function in New-Onset Type 1 Diabetes Age 12-35 Years - Within 100 Days of Diabetes Diagnosis

Non-Diabetes: Motivational Physical Activity Education Study (mPED). Women between 25 and 69 years of age

Non-Diabetes: A Mobile Phone Based Diabetes Prevention Program (mDPP). Over 35 years of age, overweight, not physically active

APS1 and Autoimmune Disease. Seeking volunteers at least 6 weeks of age who have either autoimmune disease, have evidence of autoimmunity, have a family member with autoimmunity, or do not have autoimmune disease (healthy volunteer control)

For a list of all of our trials, visit the clinical trials section of our website, or contact Lorraine Stiehl.

Diabetes Center at UCSF

Donate hereIf you wish to receive more information about the UCSF Diabetes Center’s clinical and research programs, or would like to financially support one or more of these efforts, please contact Suzanne Ritchie at 415-476-6334. You may also visit our donation webpage and/or designate your donation to the program of your choice

eUpdate is published by the Diabetes Center at UCSF. We encourage you to send this newsletter to others. If you no longer wish to receive eUpdate, you may unsubscribe at any time by sending an email to with the word “UNSUBSCRIBE” in the subject line.

Questions? Comments? We welcome your feedback at

Not interested anymore? Unsubscribe Instantly.